Hulskof schreef op 24 december 2021 23:53:
Heeft iemand hier dit meegekregen?
$AFMD — Artiva: A Thread
Many thoughts on why $AFMD collaborator, Artiva, delayed its IPO, from initial S-1 filing in April.
Their amended S-1, 12/16/21, holds the answer.
And, it also reveals that w/ a fresh start, company wants a fresh ticker:
from $RTVA to $ARTV:
t.co/rZEL3ZZyGb$AFMD — $ARTV
The cause of IPO delay was a clinical hold on lead candidate, AB-101, universal NK cell Tx, & subject of $AFMD collaboration — AFM13 & AFM24.
The clinical hold placed in April, shortly after Artiva filed initial S-1.
Reason for hold, on-study patient death:
t.co/aVBoetDusC$AFMD — $ARTV
Clinical hold was lifted in June 2021 after deemed that death was likely caused by cardiac arrhythmia, and unrelated to AB-101 Tx.
However, trial protocol required amendment, w/ patient death treated as DLT.
Delay in trial w/ cardiac safety & more pts @ initial
t.co/RUv8lWWR7j$AFMD — $ARTV
AB-101 patient dosing resumed in October 2021, and little doubt that the amendment to $AFMD collaboration agreement, also in October, was related to the protocol amendment required by clinical hold:
t.co/dmr482BHaM$AFMD — $ARTV
An unfortunate circumstance for patient & family, and for $ARTV, and reminder that with very r/r patients, on-study deaths are quite possible.
But cryopreserved possibilities may have been delayed, but doubt that they will be denied:
$AFMD — $ARTV: off the shelf
t.co/VHhUvq9HmbDe hele draad vind je hier:
twitter.com/PersimmonTI/status/147443...